Table 2.
Detailed prevalence of major comorbidities at baseline
| Total cohort (n = 13,210) | Men (n = 2558) | Women (n = 10,652) | Age < 60 y (n = 8891) | Age ≥ 60 y (n = 4319) | ||
|---|---|---|---|---|---|---|
| Comorbidities | N | Prevalence (95% CI) | N (%) | N (%) | N (%) | N (%) |
| Any major comorbidity | 559 | 4.2 (3.9–4.6) | 125 (4.9) | 434 (4.1) | 185 (2.1) | 374 (8.7) |
| Cardiovascular disease | 293 | 2.2 (2.0–2.5) | 92 (3.6) | 201 (1.9) | 72 (0.8) | 221 (5.1) |
| Stroke | 108 | 0.8 (0.7–1.0) | 40 (1.6) | 68 (0.6) | 23 (0.3) | 85 (2.0) |
| Coronary artery diseasea | 204 | 1.5 (1.3–1.8) | 59 (2.3) | 145 (1.4) | 50 (0.6) | 154 (3.6) |
| Angina pectoris | 132 | 1.0 (0.8–1.2) | 34 (1.3) | 98 (0.9) | 38 (0.4) | 94 (2.2) |
| Myocardial infarction | 50 | 0.4 (0.3–0.5) | 17 (0.7) | 33 (0.3) | 4 (0.04) | 46 (1.1) |
| Fragility fracture | 222 | 1.7 (1.5–1.9) | 26 (1.0) | 196 (1.8) | 85 (1.0) | 137 (3.2) |
| Malignancyb | 78 | 0.6 (0.5–0.7) | 15 (0.6) | 63 (0.6) | 32 (0.4) | 46 (1.1) |
| Overlap of comorbidities | ||||||
| CVD + fracture | 28 | 0.21 (0.13–0.29) | 7 (0.05) | 21 (0.16) | 4 (0.03) | 24 (0.18) |
| CVD + malignancy | 5 | 0.04 (0–0.07) | 1 (0.01) | 4 (0.03) | 0 (0) | 5 (0.04) |
| Fracture + malignancy | 1 | 0.01 (0–0.05) | 0 (0) | 1 (0.01) | 0 (0) | 1 (0.01) |
| CVD + fracture + malignancy | 0 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
CVD cardiovascular disease
aData on detailed type of CAD were missing from 22 patients
bData on organ of malignancy were missing from three RA patients with malignancies